In a space littered with failure, tiny BioSante Pharmaceuticals Inc. believes it can succeed in finally bringing a treatment for female sexual dysfunction to the U.S. market. The search for a so-called female Viagra has proved to be difficult and frustrating both for potential patients and drugmakers, with Viagra itself a high-profile failure. "Today in the U.S. there is no FDA-approved product for the treatment of women. We believe LibiGel can be first and will be an important product," BioSante chief executive Stephen Simes said in an interview about the product intended to restore loss of...
photo: AP Photo/Gregory Bull
